‘Summer SAD': How hotter temperatures can affect your mental health
While the winter's lack of sunlight leads to seasonal affective disorder (SAD) for many, there are also people who experience the same symptoms during the warmer months.
SAD is a type of depression that is triggered by the changes in the seasons, whether that be the transition into winter's colder temperatures and grayer skies, or the warmer weather and sunshine of the summer months.
Summer SAD symptoms are often thought of as the exact opposite of those of its winter counterpart. They include increased fatigue, irritability, insomnia, and anxiety. Summer SAD is also a more agitated depression, where people tend to feel more distressed than lethargic, as in winter depression.
Individuals with summer depression may be at an increased risk of suicide. Suicidal behavior peaks in the late spring and early summer, but dips in the winter.
According to clinical psychologist Adam Borland, who spoke to the Cleveland Clinic, summer SAD is caused by 'a combination of physiological and environmental issues.'
One potential cause could be feeling drained by the heat, where spending time outside results in a feeling of exhaustion.
Summer SAD could also be triggered by changes in routine that occur when the sun is out longer, resulting in someone going to bed later and possibly receiving less sleep.
'There might also be a sense of pressure to feel happier because it's summer,' Borland said. In a world filled with social media posts about people enjoying their summer, leading to feelings of not 'doing enough' with your own summer.
'Some people also express anxiety about actual physical appearance and, therefore, are avoidant of certain activities,' Borland added.
In terms of monitoring summer SAD symptoms, Borland recommends trying to stick closely to the same routine, specifically the time you wake up and go to sleep, despite the warmer weather.
He also suggested taking stock of how much time outside results in feelings of irritability, and staying cool whenever possible.
'I think it's also important for people to realize that it's not a weakness to pursue treatment options,' Borand said.
Despite all of the possible techniques and coping skills, summer SAD may sometimes be a sign of something more serious. If you are struggling to cope, seek therapy through a doctor referral or privately.
If you are experiencing feelings of distress, or are struggling to cope, you can speak to the Samaritans, in confidence, on 116 123 (UK and ROI), email jo@samaritans.org, or visit the Samaritans website to find details of your nearest branch.
If you are based in the USA, and you or someone you know needs mental health assistance right now, call or text 988, or visit 988lifeline.org to access online chat from the 988 Suicide and Crisis Lifeline. This is a free, confidential crisis hotline that is available to everyone 24 hours a day, seven days a week.
If you are in another country, you can go to www.befrienders.org to find a helpline near you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
UBS upgrades CVS, says turnaround in health benefits business gaining traction
-- UBS upgraded CVS Health (NYSE:CVS) to Buy from Neutral and raised its price target to $79, saying recent cost controls and execution in the company's healthcare benefits arm are beginning to show results and the improvement is not yet priced into the stock. The brokerage said CVS has posted two consecutive quarters of stronger-than-expected results, helped by better forecasting of Medicare Advantage utilization and early signs that fixes to its underperforming group insurance segment are working. UBS now expects CVS earnings to grow at a 14% compound annual rate through 2028, above its previous forecast and the Street's estimated 12%. Analysts pointed to CVS correctly cutting benefits and recalibrating assumptions in its Medicare Advantage plans for this year, leading to a more stable claims trend and meaningful reserve release. They estimate the group Medicare Advantage business, where roughly half of contracts are being repriced in 2025, could move from negative mid-to-high single-digit margins to positive territory, contributing an estimated $0.46 per share in 2026 earnings. UBS also expects CVS to return to roughly 3.5x leverage by late 2026, creating room for share buybacks and further earnings growth. At around nine times 2026 earnings, the stock trades below its long-term historical average of 10 times, despite a reaccelerating growth profile. Risks include potential deterioration in Medicare Star quality ratings in October, and pending U.S. regulation on drug pricing or pharmacy-benefit managers. But UBS said CVS remains confident in its Stars positioning, noting that about 65% of plan members are in contracts rated 4.5 stars or higher well above the bonus threshold. Related articles UBS upgrades CVS, says turnaround in health benefits business gaining traction Bernstein upgrades Toyota stock as journey to 20% RoE kicks off AI could deliver $920B in annual net benefits to S&P 500 firms Sign in to access your portfolio
Yahoo
7 minutes ago
- Yahoo
FDA's new expert panels are rife with financial conflicts and fringe views
WASHINGTON (AP) — When the Food and Drug Administration needs outside guidance, it normally turns to a trusted source: a large roster of expert advisers who are carefully vetted for their independence, credentials and judgment. But increasingly, the agency isn't calling them. Instead, FDA Commissioner Marty Makary has launched a series of ad hoc 'expert panels' to discuss antidepressants, menopause drugs and other topics with physicians and researchers who often have contrarian views and financial interests in the subjects. Former agency officials worry the meetings are skirting federal rules on conflicts of interests and transparency, while promoting fringe viewpoints that align with those of Health Secretary Robert F. Kennedy Jr. 'These meetings are a chance to advance RFK's pet peeves — talc, antidepressants, fluoride — with people who have been handpicked,' said Dr. Peter Lurie, a former FDA official who is now president of the Center for Science in the Public Interest. 'Nobody would put forward these panels as representing the general scientific opinion on these topics.' A spokesperson for Kennedy did not answer specific questions about the panels, but said they represent an effort to 'apply rigorous, evidence-based standards to ingredient safety and modernize regulatory oversight.' The panels kicked off in May with a meeting on talc, the soft mineral sometimes added to makeup, baby powder and other consumer goods. The meeting echoed thousands of lawsuits alleging talc has contributed to ovarian cancer and other illnesses, and included two experts who testified in those cases. Under FDA regulations, the ingredient is still considered safe when carefully tested for the presence of asbestos. And federally funded studies haven't shown a link to cancer. A July meeting on the safety of antidepressants during pregnancy also featured doctors who have testified in class action lawsuits, alongside other experts who allege the drugs cause autism, birth defects and other conditions — links that are not supported by science. The meeting concluded with all but one of the experts calling for a new boxed warning — the most serious type — about antidepressant risks for mothers and developing babies. A meeting on estrogen-based drugs for menopause took the opposite approach: Experts urged the removal of a long-standing warning. Most of the physicians at that meeting prescribe the hormones or are involved with a pharmaceutical industry campaign opposing the warning label. Nearly 80 researchers sent a letter to the FDA this month objecting to the 'two-hour meeting of hormone proponents' and calling for an official advisory committee meeting. Advisory panels operate under strict rules The FDA has more than 30 panels composed of experts specializing in various drugs, vaccines, food ingredients and other products. Their meetings are subject to strict government transparency rules in terms of scheduling, panel composition and disclosure of any financial conflicts. A comment period open to the public is also required. Additionally, FDA scientists usually publish a detailed memo explaining their position on the topic. The latest FDA meetings haven't included those elements. Former FDA lawyers say the agency could expose itself to legal challenges if it tries to use Makary's informal panels as the basis for regulatory decisions. But that may not be the aim of the meetings. 'They seem more designed as a forum to put a stamp of approval on predetermined opinions,' said Genevieve Kanter, a health policy specialist at the University of Southern California. 'The information in these panels could be used in litigation and presented as coming from experts or representing some intellectual consensus that doesn't exist.' Antidepressants meeting aired unfounded claims Antidepressants have long been a target of Kennedy, an attorney and outspoken critic of pharmaceutical companies. During his confirmation hearings he suggested, without evidence, that the drugs contribute to school shootings. The FDA's recent session cataloged many unsubstantiated theories about the drugs, often based on animal studies, including that they contribute to autism, birth defects and miscarriages. Several participants had served as expert witnesses against drugmakers, including in lawsuits alleging that they cause homicidal behavior. All but one of the other panelists have criticized the drugs in books, articles, interviews or other forums. 'It's never been possible to identify a group of people who do particularly well on antidepressants,' said Dr. Joanna Moncrieff, a British psychiatrist, author and co-founder a group critical of mainstream psychiatric medicine. The American College of Obstetricians and Gynecologists called the panel 'alarmingly unbalanced' and full of 'outlandish and unfounded claims.' Antidepressants carry pregnancy warnings about risks of excess bleeding and lower birth weight for newborns. But psychiatric experts say those risks are far outweighed by the well-documented harms of untreated depression in mothers, which can lead to pregnancy complications, substance abuse and suicide. 'I tell people I'm working with that the best thing they can do for themselves and their baby is to get the treatment that they need,' said Dr. Nancy Byatt of University of Massachusetts' Chan Medical School. Financial conflicts at menopause meeting FDA has not disclosed how panelists were selected for the meetings. Last month's session on hormone therapies for menopause included doctors who consult for drugmakers or promote the medications in their practices. The views they expressed largely echoed those of Makary, who has argued that current warning labels overstate hormone therapy risks and don't reflect possible benefits for some women, such as reducing heart disease and cognitive decline. 'Hormone replacement therapy for women is basically a modern-day miracle,' Makary told a podcast host last year. But guidance from the FDA and other top federal authorities specifically advises against using the drugs to prevent chronic conditions due to a lack of clear benefit. The drugs are only FDA-approved for specific menopause symptoms, including hot flashes. Discussions around hormone therapy reflect ongoing debate about a landmark study of two different hormone regimens in more than 26,000 postmenopausal women. The research was halted more than 20 years ago because scientists discovered that the risk of serious health problems outweighed the benefits. All estrogen drugs still carry boxed warnings about the higher rates of stroke, blood clots and cognitive problems among women taking the medications. But some doctors — including those at FDA's meeting — say the warnings are exaggerated and should be removed from at least some products, such as low-dose creams typically used for vaginal dryness. Makary raised the possibility of also removing the warning from higher-dose pills, patches and sprays. It's unclear whether the FDA will move ahead with those changes or heed calls for an official advisory meeting — a step that Kennedy's critics say would be in keeping with his pledge for 'radical transparency.' 'If you really wanted to be transparent about these issues you'd put together a balanced panel of experts, who have been carefully screened for conflicts and you'd invite the public in,' Lurie said. 'But that's the antithesis of what's going on in these cases.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Matthew Perrone, The Associated Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.
Live video webcast on Thursday, August 21st at 1:00 PM ET Register here THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer will participate in a virtual investor webinar hosted by Ladenburg Thalmann on Thursday, August 21, 2025 and 1:00 PM ET. The webinar will be moderated by Jeffrey S. Cohen, Managing Director and Director of Equity Research of Ladenburg Thalmann. Following the discussion, there will be a question and answer session. Interested participants may pre-submit questions to events@ ahead of the event. To register for the webinar, please click here. The webinar will also be accessible on the Events page in the Investors section of the Company's website ( About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit and connect with the Company on X, LinkedIn, Instagram and Facebook. Investor and Media Contact JTC Team, LLCJenene Thomas (908) 824-0775autonomix@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
